دورية أكاديمية
Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa.
| العنوان: | Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa. |
|---|---|
| المؤلفون: | Bauer M; Department of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.; Global Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Vetter M; Department of Gynecology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Stückrath K; Department of Gynecology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Yohannes M; Department of Medical Laboratory Science, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia., Desalegn Z; Department of Microbiology, Immunology & Parasitology, School of Medicine, College of Health Sciences, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia., Yalew T; Department of Pathology, Tikur Anbessa Specialized University Hospital, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia., Bekuretsion Y; Department of Pathology, Tikur Anbessa Specialized University Hospital, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia., Kenea TW; Department of Surgery, Aira General Hospital, Aira, Ethiopia., Joffe M; Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa.; Strengthening Oncology Services Research Unit, Faculty of Health Sciences, Univeristy of Witwatersrand, Johannesburg, South Africa.; SAMRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., van den Berg EJ; Department of Anatomical Pathology, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa., Nikulu JI; Ligue Congolaise Contre le Cancer, l'Unité Pilote du GFAOP, Lubumbashi, Democratic Republic of the Congo., Bakarou K; Service d'Anatomie, Cytologie Pathologique au C.H.U. du point G, BP 333, Bamako, Mali., Manraj SS; Central Health Laboratory, Victoria Hospital, Candos, Mauritius., Ogunbiyi OJ; Department of Pathology, University College Hospital, Ibadan, Nigeria., Ekanem IO; Department of Pathology, Calabar Cancer Registry, University of Calabar Teaching Hospital, Calabar, Nigeria., Igbinoba F; National Hospital, Abuja, Nigeria., Diomande M; Service d'Anatomie et Cytologie Pathologiques, Abidjan, Côte d'Ivoire., Adebamowo C; Department of Epidemiology and Public Health, and the Marlene and Stewart Greenebaum, Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland., Dzamalala CP; Department of Pathology, Malawi College of Medicine, Blantyre, Malawi., Anele AA; Federal Medical Centre, Owerri, Nigeria., Zietsman A; AB May Cancer Centre, Windhoek Central Hospital, Windhoek, Namibia., Galukande M; College of Health Sciences, Makerere University, Kampala, Uganda., Foerster M; International Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, Lyon, France., Dos-Santos-Silva I; Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine (LSHTM), London, United Kingdom., Liu B; African Cancer Registry Network, Oxford, United Kingdom., Santos P; Global Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Jemal A; Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia., Abebe T; Department of Medical Laboratory Science, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia., Wickenhauser C; Department of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Seliger B; Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.; Institute of Translational Immunology, Medical School Theodor Fontane, Brandenburg an der Havel, Germany.; Fraunhofer Institute for Immunology, Leipzig, Germany., McCormack V; International Agency for Research on Cancer (IARC/WHO), Environment and Lifestyle Epidemiology Branch, Lyon, France., Kantelhardt EJ; Global Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.; Department of Gynecology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. |
| المصدر: | Cancer immunology research [Cancer Immunol Res] 2023 Jun 02; Vol. 11 (6), pp. 720-731. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research, [2013]- |
| مواضيع طبية MeSH: | Tumor Microenvironment* , Neoplasms*/pathology, Prognosis ; Cohort Studies ; Lymphocytes, Tumor-Infiltrating ; Macrophages |
| مستخلص: | The low overall survival rates of patients with breast cancer in sub-Saharan Africa (SSA) are driven by regionally differing tumor biology, advanced tumor stages at diagnosis, and limited access to therapy. However, it is not known whether regional differences in the composition of the tumor microenvironment (TME) exist and affect patients' prognosis. In this international, multicentre cohort study, 1,237 formalin-fixed, paraffin-embedded breast cancer samples, including samples of the "African Breast Cancer-Disparities in Outcomes (ABC-DO) Study," were analyzed. The immune cell phenotypes, their spatial distribution in the TME, and immune escape mechanisms of breast cancer samples from SSA and Germany (n = 117) were investigated using histomorphology, conventional and multiplex IHC, and RNA expression analysis. The data revealed no regional differences in the number of tumor-infiltrating lymphocytes (TIL) in the 1,237 SSA breast cancer samples, while the distribution of TILs in different breast cancer IHC subtypes showed regional diversity, particularly when compared with German samples. Higher TIL densities were associated with better survival in the SSA cohort (n = 400), but regional differences concerning the predictive value of TILs existed. High numbers of CD163+ macrophages and CD3+CD8+ T cells accompanied by reduced cytotoxicity, altered IL10 and IFNγ levels and downregulation of MHC class I components were predominantly detected in breast cancer samples from Western SSA. Features of nonimmunogenic breast cancer phenotypes were associated with reduced patient survival (n = 131). We therefore conclude that regional diversity in the distribution of breast cancer subtypes, TME composition, and immune escape mechanisms should be considered for therapy decisions in SSA and the design of personalized therapies. See related Spotlight by Bergin et al., p. 705. (©2023 American Association for Cancer Research.) |
| التعليقات: | Comment in: Cancer Immunol Res. 2023 May 12;:OF1-OF2. (PMID: 37171377) Comment in: Cancer Immunol Res. 2023 Jun 2;11(6):705-706. (PMID: 37264817) |
| References: | Mediators Inflamm. 2015;2015:816460. (PMID: 26089604) Immunol Rev. 2018 May;283(1):176-193. (PMID: 29664568) Lancet Glob Health. 2020 Sep;8(9):e1203-e1212. (PMID: 32827482) Breast Cancer Res Treat. 2017 Feb;161(3):491-499. (PMID: 27915434) J Clin Oncol. 2019 Mar 1;37(7):559-569. (PMID: 30650045) Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310) Breast. 2018 Dec;42:23-30. (PMID: 30149234) Lancet Oncol. 2018 Jan;19(1):40-50. (PMID: 29233559) PLoS One. 2019 Nov 8;14(11):e0224760. (PMID: 31703083) Diagnostics (Basel). 2022 Oct 18;12(10):. (PMID: 36292215) J Clin Med. 2019 Dec 08;8(12):. (PMID: 31817953) Ann Oncol. 2015 Feb;26(2):259-71. (PMID: 25214542) Cancer Discov. 2022 Nov 2;12(11):2530-2551. (PMID: 36121736) Cancers (Basel). 2021 Jan 07;13(2):. (PMID: 33430322) J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34620701) Breast Cancer. 2018 Jan;25(1):34-42. (PMID: 28488168) Breast Cancer Res Treat. 2021 Apr;186(2):391-401. (PMID: 33576900) Ther Adv Med Oncol. 2022 Feb 08;14:17588359221075458. (PMID: 35154416) Pathol Int. 2012 May;62(5):303-8. (PMID: 22524657) Arch Pathol Lab Med. 2011 Feb;135(2):194-9. (PMID: 21284437) BMC Cancer. 2017 Feb 7;17(1):115. (PMID: 28173783) JCO Precis Oncol. 2022 Nov;6:e2200341. (PMID: 36446041) NPJ Breast Cancer. 2022 Jul 22;8(1):88. (PMID: 35869114) Onco Targets Ther. 2016 Aug 12;9:5023-39. (PMID: 27574444) Cancer Causes Control. 2022 Jun;33(6):831-841. (PMID: 35384527) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Front Oncol. 2020 Jun 30;10:1022. (PMID: 32714862) J Clin Pathol. 1995 Sep;48(9):876-8. (PMID: 7490328) NPJ Breast Cancer. 2022 Aug 9;8(1):92. (PMID: 35945417) Mutat Res. 2022 Jan-Jun;824:111776. (PMID: 35247630) Exp Biol Med (Maywood). 2021 Jun;246(12):1377-1387. (PMID: 33926257) Methods Enzymol. 2020;635:67-79. (PMID: 32122554) Clin Cancer Res. 2011 May 1;17(9):2668-78. (PMID: 21248298) Cancer Cell. 2018 Oct 8;34(4):549-560.e9. (PMID: 30300578) Breast Cancer Res Treat. 2023 Jun;199(2):401-413. (PMID: 37010652) Ann Oncol. 2011 Aug;22(8):1736-47. (PMID: 21709140) Cancer Discov. 2017 Oct;7(10):1098-1115. (PMID: 28652380) BMC Cancer. 2014 Nov 29;14:895. (PMID: 25433805) JCI Insight. 2017 Jul 20;2(14):. (PMID: 28724788) Breast Cancer Res Treat. 2019 May;175(1):247-259. (PMID: 30725384) Hum Immunol. 2001 Feb;62(2):133-9. (PMID: 11182222) Breast Care (Basel). 2018 Mar;13(1):16-21. (PMID: 29950962) BMC Cancer. 2018 May 11;18(1):556. (PMID: 29751789) ESMO Open. 2020 Oct;5(5):e000829. (PMID: 33020218) Breast Cancer Res Treat. 2012 Oct;135(3):867-73. (PMID: 22915073) Br J Cancer. 2020 Feb;122(4):539-544. (PMID: 31806878) BMC Cancer. 2016 Mar 10;16:204. (PMID: 26964534) Am J Hum Genet. 2005 Oct;77(4):676-80. (PMID: 16175514) Genome Biol. 2009;10(12):R141. (PMID: 20025784) Int Rev Immunol. 2009;28(3-4):239-60. (PMID: 19811323) Brief Bioinform. 2021 Mar 22;22(2):2020-2031. (PMID: 32141494) J Natl Cancer Inst. 2009 Jul 15;101(14):984-92. (PMID: 19584328) PLoS Med. 2014 Sep 09;11(9):e1001720. (PMID: 25202974) Cancer Immunol Res. 2020 Apr;8(4):422-427. (PMID: 32238387) J Natl Cancer Inst. 2021 Aug 2;113(8):1036-1043. (PMID: 33395700) J Clin Oncol. 2006 Mar 20;24(9):1342-9. (PMID: 16549828) Breast Cancer Res Treat. 2022 Dec;196(3):495-504. (PMID: 36282363) Breast Care (Basel). 2020 Oct;15(5):481-490. (PMID: 33223991) JAMA. 2002 Apr 24;287(16):2106-13. (PMID: 11966385) Int J Cancer. 2018 Apr 15;142(8):1568-1579. (PMID: 29197068) Front Oncol. 2021 Apr 15;11:650117. (PMID: 33937056) Nat Commun. 2021 Nov 26;12(1):6946. (PMID: 34836952) Nat Rev Cancer. 2015 Apr;15(4):248-54. (PMID: 25673085) Clin Cancer Res. 2019 Aug 15;25(16):5002-5014. (PMID: 30837276) |
| معلومات مُعتمدة: | 001 International WHO_ World Health Organization; R01 CA192627 United States CA NCI NIH HHS; R01 CA244559 United States CA NCI NIH HHS; R01 CA250012 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20230414 Date Completed: 20230605 Latest Revision: 20240324 |
| رمز التحديث: | 20240324 |
| مُعرف محوري في PubMed: | PMC10552870 |
| DOI: | 10.1158/2326-6066.CIR-22-0795 |
| PMID: | 37058582 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2326-6074 |
|---|---|
| DOI: | 10.1158/2326-6066.CIR-22-0795 |